Evotec SE (EVO) Other Non-Current Liabilities (2009 - 2026)
Evotec SE (EVO) reported Other Non-Current Liabilities of $153164.0 for Q1 2026, up 113.76% on a YoY basis from $71653.3 in Q1 2025, and up 124.76% sequentially from $68146.6 in Q4 2025.
Evotec SE (EVO) Other Non-Current Liabilities (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 9 years of Other Non-Current Liabilities data on file, last reported at $153164.0 in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 113.76% year-over-year to $153164.0; the trailing twelve-month figure through Mar 2026 stood at $153164.0 (up 113.76% YoY), and the FY2025 full-year result was $68146.6, down 99.67% from the prior year.
- Other Non-Current Liabilities advanced to $153164.0 in Q1 2026, from $68146.6 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $20.9 million in Q4 2024 to a low of -$404.41 in Q2 2022.
- A 5-year average of $4.6 million and a median of $69900.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- Across the five-year window, Other Non-Current Liabilities sank 99.67% in 2025 and soared 113.76% in 2026, its largest moves.
- Tracing EVO's Other Non-Current Liabilities over 5 years: stood at $16.8 million in 2022, then rose by 3.12% to $17.3 million in 2023, then increased by 21.09% to $20.9 million in 2024, then slumped by 99.67% to $68146.6 in 2025, then surged by 124.76% to $153164.0 in 2026.
- Business Quant data shows EVO's Other Non-Current Liabilities at $153164.0 in Q1 2026, $68146.6 in Q4 2025, and $50673.9 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Evotec SE | 351.60 Mn | 351.08 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153,163.97 |
| Dec 31, 2025 | 68,146.60 |
| Sep 30, 2025 | 50,673.86 |
| Jun 30, 2025 | 54,518.57 |
| Mar 31, 2025 | 71,653.32 |
| Dec 31, 2024 | 20.93 Mn |
| Sep 30, 2024 | 74,327.50 |
| Dec 31, 2023 | 17.28 Mn |
| Dec 31, 2022 | 16.76 Mn |
| Sep 30, 2022 | 33,091.56 |
| Jun 30, 2022 | -404.41 |
| Mar 31, 2022 | 53,646.62 |
| Dec 31, 2021 | 20.62 Mn |
| Sep 30, 2021 | 50,296.60 |
| Dec 31, 2020 | 24.72 Mn |
| Sep 30, 2010 | 9,086.69 |
| Jun 30, 2010 | 3,032.84 |
| Mar 31, 2010 | 1,142.39 |
| Dec 31, 2009 | 7,173.97 |
| Aug 31, 2009 | 93.19 |